Lee S, Matsuzaki H, Kumagai-Takei N, Yoshitome K, Maeda M, Chen Y
Environ Health Prev Med. 2014; 19(5):322-9.
PMID: 25135741
PMC: 4166593.
DOI: 10.1007/s12199-014-0403-9.
Iizuka Y, Iizuka H, Tsutsumi S, Nakagawa Y, Nakajima T, Sorimachi Y
Eur Spine J. 2009; 18(10):1431-5.
PMID: 19533181
PMC: 2899376.
DOI: 10.1007/s00586-009-1061-2.
Tatsumi M, Sugahara H, Higuchi I, Fukunaga H, Nakamura H, Kanakura Y
Int J Clin Oncol. 2009; 14(2):150-8.
PMID: 19390947
DOI: 10.1007/s10147-008-0823-x.
Caruso C, Candore G, Cigna D, Colucci A, Modica M
Mediators Inflamm. 1993; 2(1):3-21.
PMID: 18475497
PMC: 2365387.
DOI: 10.1155/S0962935193000018.
Itoh M, Ohta Y, Goto Y, Ohashi H
Clin Rheumatol. 1998; 17(1):26-30.
PMID: 9586675
DOI: 10.1007/BF01450954.
LW/SO cell line: a tool for studying the phenotypical characterization and commitment of hematopoietic stem cells.
Oez S, Trautmann U, Smetak M, Birkmann J, al salemeh S, Gebhart E
Ann Hematol. 1996; 72(5):307-16.
PMID: 8645743
DOI: 10.1007/s002770050177.
Levels of soluble interleukin-2 receptors are predictive of response in patients treated with interleukin-2 and lymphokine-activated killer cells.
Paietta E, Nelson D, Andersen J, Dutcher J, Wiernik P
Med Oncol. 1995; 12(2):121-4.
PMID: 8535662
DOI: 10.1007/BF01676713.
Membrane-bound and soluble IL-2 receptors (p55 and p75 chains) on peripheral blood mononuclear cells from patients with solid malignancies.
Mantovani G, Maccio A, Astara G, Contini L, Esu S, Littera S
Cell Biophys. 1993; 22(1-3):79-99.
PMID: 7889544
DOI: 10.1007/BF03033868.
Membrane-bound/soluble IL-2 receptor (IL-2R) and levels of IL-1 alpha, IL-2, and IL-6 in the serum and in the PBMC culture supernatants from 17 patients with hematological malignancies.
Mantovani G, Maccio A, Lai P, Ghiani M, Turnu E, DEL GIACCO G
Cell Biophys. 1995; 27(1):1-14.
PMID: 7493395
DOI: 10.1007/BF02822523.
Increased serum levels of soluble interleukin-2 receptor in patients with systemic lupus erythematosus and rheumatoid arthritis.
Semenzato G, Bambara L, Biasi D, Frigo A, Vinante F, Zuppini B
J Clin Immunol. 1988; 8(6):447-52.
PMID: 3065351
DOI: 10.1007/BF00916949.
Serum levels of soluble interleukin-2 receptor in pulmonary tuberculosis.
Choi S, Moon Y, Lee B, Kim D
Korean J Intern Med. 1990; 5(1):44-50.
PMID: 2271510
PMC: 4534993.
DOI: 10.3904/kjim.1990.5.1.44.
Longitudinal survey in an endemic region of plasma soluble interleukin-2 receptor and antibody levels in Plasmodium falciparum malaria.
Chumpitazi B, Peyron F, Simon J, Boudin C, Picot S, Ambroise-Thomas P
J Clin Microbiol. 1990; 28(7):1545-50.
PMID: 2199518
PMC: 267986.
DOI: 10.1128/jcm.28.7.1545-1550.1990.
Increased levels of soluble interleukin-2 receptors in serum of patients with lung cancer.
Marino P, Cugno M, Preatoni A, Cori P, ROSTI A, Frontini L
Br J Cancer. 1990; 61(3):434-5.
PMID: 2158340
PMC: 1971291.
DOI: 10.1038/bjc.1990.95.
A disturbance of the IL-2/IL-2 receptor system parallels the activity of multiple myeloma.
Vacca A, Di Stefano R, Frassanito A, Iodice G, Dammacco F
Clin Exp Immunol. 1991; 84(3):429-34.
PMID: 2044221
PMC: 1535424.
Soluble interleukin-2 receptor and soluble CD8 antigen levels in serum from patients with non-resectable lung cancer.
Vibe-Petersen J, Tvede N, Diamant M, Kjerulff A, SORENSEN H, Andersen V
Cancer Immunol Immunother. 1991; 33(2):121-7.
PMID: 1903673
PMC: 11038207.
DOI: 10.1007/BF01742540.
Lymphocyte activation in patients with acute myeloid leukaemia. Evidence for the presence of myeloblast antigen?.
Lim S, Worman C, Goldstone A
Cancer Immunol Immunother. 1991; 33(6):417-20.
PMID: 1878895
PMC: 11041054.
DOI: 10.1007/BF01741604.
